First-line maintenance Approaches | Response & Response Duration   
Aggressive Approaches | Survival

Also see Refractory

First-line
maintenance

Return to top

1a. Current treatment of follicular and low-grade non-Hodgkin's lymphoma. Anticancer Drugs. 2001 Jun;12 Suppl 2:S5-9. Review. PMID: 11508934 abstract | Related_abstracts

2a. Quality of life in patients with low-grade non-Hodgkin's lymphoma. 
Oncology (Huntingt). 1998 May;12(5):697-714; discussion 714, 717, 721. Review.
PMID: 9597680 abstract

3a. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial. abstract

4a. Vaccine Therapies for Non-Hodgkin's Lymphoma. Curr Treat Options Oncol. 2002 Aug;3(4):307-15. PMID: 12074767  PubMed

Response & Response Duration

Also see
 Time to Progression

Return to top

1b. Each Subsequent Therapy Results in Diminishing Response Rate and Duration of Response in Low Grade or Transformed Low Grade Non-Hodgkin's Lymphoma.  ASCO 2001 Abstract 1165 

2b. Time to Progression Table  Lymphomation.org

3b. Stage III follicular lymphoma: long-term follow-up and patterns of failure.
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):748-54  PMID: 14529780

Aggressive approaches
 
with the goal of achieving molecular remissions, long-term disease-free survival, and possible cures

There is hope that the  following types of therapies may cure some patients with indolent NHL in some treatment settings

Note: For aggressive NHL, the goal of initial treatment is to cure.

CHOP + Rituxan

Transplants

Therapeutic vaccines

Radiotherapy

Other combinations

Return to top

1c. Can we cure indolent lymphomas? Clin Cancer Res. 1997 Dec;3(12 Pt 2):2655-9. Review.
PMID: 10068269 PubMed

2c. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Semin Oncol. 2002 Feb;29(1 Suppl 2):36-40. PMID: 11842387 PubMed

3c. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15;98(13):3595-9 PubMed

4c. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999 Oct;5(10):1171-7. PMID: 10502821 PubMed

5c. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol. 2002 Mar;68(3):144-9. PMID: 12068794  PubMed

6c. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. [in patients with nodal bulky disease] - Eur J Haematol 2002: 68: 144-149  PDF | PDFHelp

7c. Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. Hematol Oncol. 2003 Sep;21(3):99-108  PMID: 14579238 

8c. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma. 2003 Nov; 44(11): 1911-7  PMID: 14738142 | Related articles

Radiotherapies

1r. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. [in patients with nodal bulky disease] - Eur J Haematol 2002: 68: 144-149  PDF | PDFHelp

2r. Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial.
Eur J Haematol. 2002 Mar;68(3):144-9. PMID: 12068794  PubMed

3r. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer. 1995 May 1;75(9):2361-7. PMID: 7712449  PubMed

Survival & Durable Responses

Return to top

1d. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma.
Acta Oncol. 2001;40(2-3):213-23. Review. PMID: 11441933 abstract

2d. Non-Hodgkin's lymphoma: review of conventional treatments. Curr Pharm Biotechnol. 2001 Dec;2(4):279-91. PMID: 11762410 abstract

3d. Horning S, Rosenberg S: The natural history of initially untreated low-grade non-Hodgkins lymphomas. N Engl J Med 311:1471-1475, 1984.)

4d. The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas 
By Armando López-Guillermo, Fernando Cabanillas, Peter McLaughlin, Terry Smith, Fredrick Hagemeister, María A. Rodríguez, Jorge E. Romaguera, Anas Younes, Andreas H. Sarris, H. Alejandro Preti, William Pugh, and Ming-Seng Lee  

Blood, Vol. 91 No. 8 (April 15), 1998: pp. 2955-2960  bloodjournal.org full text

5d.  The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma. 2003 Nov; 44(11): 1911-7  PMID: 14738142 | Related articles